Dendreon CFO bails for job at StemCells; India's Sun Pharma raises growth forecast to 25%;

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Dendreon ($DNDN) CFO Greg Schiffman has jumped ship to StemCells, where he will take over as CFO and executive vice president of finance. Release

> India's Sun Pharma hiked its outlook for fiscal 2014 revenue growth to 25% from its previously forecast 18-20%; its quarterly net sales grew by 58% to 41.92 billion rupees, or $664 million. Report

> Despite an extended period of shutdowns and cutbacks in the region, drugmakers still account for a $26.6 billion boost to the New Jersey economy. Report

> India's Strides Arcolab saw third-quarter profits slump because of foreign exchange losses and regulatory delays, but the company stuck to its forecast for the year. Report

> Novartis' ($NVS) generics unit Sandoz recalled a mispackaged batch of tuberculosis drugs from 5 states in India. Report

> The Slovenian drugmaker Krka posted a 12% increase in profits for the first 9 months of the year, to $1.67 million. Report

Medical Device News

@FierceMedDev: Analysts: Volcano could be an M&A fit for Abbott, Medtronic. More | Follow @FierceMedDev

@MarkHFierce: Inspired by a wine cork removal device, an Argentinian mechanic developed a surgical tool to aid difficult births. Story | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery: DNA-delivering patch spurs bone growth. Piece | Follow @MichaelGFierce

> Tandem banks $120M in topped-out IPO, stirring med tech market hopes. Article

> Biomet hit with metal hip lawsuit in Canada. More

Biotech News

@FierceBiotech: Merck KGaA says big M&A could jump-start stilted pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Best case scenario for Lemtrada: FDA OKs for a very limited group of desperate patients. | Follow @JohnCFierce

@DamianFierce: Sanofi gets mixed FDA blessing for MS drug Lemtrada. More | Follow @DamianFierce

@EmilyMFierce: Tuberculosis R&D dropped by $30.4 million in 2012 compared with 2011. Report | Follow @EmilyMFierce

> Trio of IPO setbacks strike sour note at biotech's Wall Street party. News

> Novartis, Novavax whip up new bird flu vaccines as pandemic fears flourish. Article

> Theravance scraps ADHD program after drug flunks PhII study. More

Vaccines News

> Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine. Story

> Novartis to sell first piece of vaccine unit in $1.7B deal. Article

> Polio outbreak sparks fears refugees will carry virus to Europe. Report

> Dendreon to lay off more staff as Provenge disappoints. Again. More

> Novavax presents positive Phase I data for H7N9 vaccine. Story

> U.K. adds schools to flu data-gathering project. Item

Pharma Manufacturing News

> Track-and-trace bill may be finished this week. Article

> Lilly to invest $700M in plant expansions. More

> Sandoz pulls some TB drugs in India. Report

> Dendreon hopes manufacturing can save the day. Story

> FDA red-flags dangerous counterfeit ED product. Article

> New manufacturing processes could produce bird flu vax ASAP. Item

And Finally... Diabetes now kills one person every 6 seconds and affects 382 million people worldwide. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.